Qianqian Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Qianqian Wang has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Di Xiong
Department of General Medicine, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, China
3 shared publicationsXiaodong Wang
Department of Radiation Oncology, Cancer Center & Institution of Stress Medicine, West China Hospital, Sichuan University, Chengdu, China
3 shared publications- Bingwen Zou
Department of Radiation Oncology, Cancer Center & Institution of Stress Medicine, West China Hospital, Sichuan University, Chengdu, China
2 shared publications - Junjie Wang
Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China
2 shared publications Songli Cui
Department of Oncology, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, China
2 shared publications- Yeqian Feng
Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China
2 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by Springer Nature in Cancer Cell International
Artificial intelligence for predicting immune checkpoint inhibitor outcomes through multi-omics integration
- 26 October 2026
- Published by Springer Nature in Cancer Cell International
Open AccessArtificial intelligence for predicting immune checkpoint inhibitor outcomes through multi-omics integration
- Open Access
- 20 September 2026
- Published by Springer Nature in Molecular Cancer
- Vol. 25 (1) , 222
Immune-pressure redistribution in resistance to PD-1/PD-L1 blockade: mechanisms, biomarkers, and therapeutic design
PD-1/PD-L1 blockade can produce durable tumor control, yet primary, adaptive, and acquired resistance remain common. Existing accounts often catalogue resi
- 20 September 2026
- Published by Springer Nature in Molecular Cancer
- Vol. 25 (1) , 222
Open AccessImmune-pressure redistribution in resistance to PD-1/PD-L1 blockade: mechanisms, biomarkers, and therapeutic design
PD-1/PD-L1 blockade can produce durable tumor control, yet primary, adaptive, and acquired resistance remain common. Existing accounts often catalogue resi
- Open Access
- 31 July 2026
- Published by Springer Nature in Molecular Cancer
- Vol. 25 (1) , 211
Ecosystem-matched reprogramming of the tumor–immune microenvironment to overcome cancer immunotherapy resistance
- 31 July 2026
- Published by Springer Nature in Molecular Cancer
- Vol. 25 (1) , 211
Open AccessEcosystem-matched reprogramming of the tumor–immune microenvironment to overcome cancer immunotherapy resistance
- Top Cited PapersOpen Access
- 20 April 2026
- Published by Springer Nature in Cellular Oncology
- Vol. 49 (3)
Lactate signaling and immune suppression in tumors: mechanisms and therapeutic implications
Lactate is no longer viewed as a passive end-product of the Warburg effect; instead, it plays an active role in shaping tumor biology and immune responses. In solid tumors, enhanced glycolysis and lactate export, along with proton handling, generate steep lactate and acidosis gradients that exert selective pressure on immune cells. Beyond competition for resources, lactate signals through specific receptors and drives epigenetic changes via lactylation, altering the transcriptional profiles of tumor, stromal, and immune cells. These processes lead to the suppression of cytotoxic T cells and natural killer cells, impair antigen presentation, and promote regulatory T cells and myeloid suppressor cells, which collectively contribute to the development of immune-resistant “cold” microenvironments. Targeting the lactate signaling pathway, whether by inhibiting lactate production, transport, pH buffering, or receptor signaling, provides a promising strategy to counteract metabolic immune suppression. This review integrates recent findings on lactate-driven immune remodeling, identifies potential therapeutic targets, and discusses how these strategies can be combined with immunotherapy and cellular treatments to improve outcomes. We also highlight the need for biomarkers to assess lactate-specific effects and distinguish them from those caused by acidosis.
- 20 April 2026
- Published by Springer Nature in Cellular Oncology
- Vol. 49 (3)
Top Cited PapersOpen AccessLactate signaling and immune suppression in tumors: mechanisms and therapeutic implications
Lactate is no longer viewed as a passive end-product of the Warburg effect; instead, it plays an active role in shaping tumor biology and immune responses. In solid tumors, enhanced glycolysis and lactate export, along with proton handling, generate steep lactate and acidosis gradients that exert selective pressure on immune cells. Beyond competition for resources, lactate signals through specific receptors and drives epigenetic changes via lactylation, altering the transcriptional profiles of tumor, stromal, and immune cells. These processes lead to the suppression of cytotoxic T cells and natural killer cells, impair antigen presentation, and promote regulatory T cells and myeloid suppressor cells, which collectively contribute to the development of immune-resistant “cold” microenvironments. Targeting the lactate signaling pathway, whether by inhibiting lactate production, transport, pH buffering, or receptor signaling, provides a promising strategy to counteract metabolic immune suppression. This review integrates recent findings on lactate-driven immune remodeling, identifies potential therapeutic targets, and discusses how these strategies can be combined with immunotherapy and cellular treatments to improve outcomes. We also highlight the need for biomarkers to assess lactate-specific effects and distinguish them from those caused by acidosis.